Cell therapy investment grows as safety events rankle Big Pharma’s CAR T autoimmune push

Sail Biomedicine’s $925 million deal with Johnson & Johnson helped boost the cell and gene therapy sector over biologics in terms of venture capital fundraising in the third quarter.